Funding & Investment

Bay Area Lyme Ventures invests in LymeLess Health's 'Ella' app, an AI tool born from personal struggle, aiming to transform patient care and research.

Vexev’s AI-powered robotic ultrasound platform just raised $6M to tackle the specialist shortage and transform cardiovascular disease diagnostics for millions.

Phoenix Nest secures a pivotal $3M NIH grant to manufacture a potential cure for Sanfilippo syndrome, a fatal childhood disease with no current treatment.

Dentist-led startup Lewie seeks $3M, signaling rising investor interest in the 'oral beauty' market where wellness, design, and tech converge.

Danantara's new financing panel aims to mobilize billions for waste-to-energy. It's a massive green opportunity, but can investors navigate the risks?

With a veteran team from Meta and Snowflake and a massive $180M war chest, Glow is betting it can win the AI security arms race with a radical new model.

A $15.97M federal grant will help Virginia's APM Tech Hub create a fully domestic drug supply chain, tackling critical shortages and boosting US manufacturing.

New biotech Rinascera launches with a veteran team and a clinical-stage pipeline. Is its disciplined, asset-acquisition strategy the future for rare diseases?

CraniUS Therapeutics secures up to $4M in NIH funding for its NeuroPASS device, a refillable implant aiming to revolutionize glioblastoma and CNS treatment.

A federal AI investment is coming. But the real story isn’t the cheque—it’s the strategic alignment of ministers and the choice of venue. Here's what it signals.

With Japan facing a 'knowledge bomb' from a retiring workforce, Trupeer AI bets on a UiPath veteran to build the one thing enterprise AI is missing: context.

AIXAlpha promises to make volatile crypto markets accessible to all. But as automation replaces experience, are investors gaining an edge or just new risks?

Led by an Anker veteran, ETOE launches its premium Dolphin 2 projector. Can its RGB triple-laser tech and smart features disrupt the crowded market?

At BIO 2026, Fapon Group unveils a novel strategy combining T-cell engagers and in vivo CAR-T to target complex diseases. What does this mean for the future?

A small travel platform bets big on North America-India routes, promising deep discounts and a better experience. But can it deliver against industry giants?

Defiance ETFs launches Europe's first memory-focused fund as analysts predict prices could soar 130%, reshaping the entire global technology supply chain.

Arverne CEO Pierre Brossollet's move to increase his stake is more than a vote of confidence; it's a strategic key unlocking a €70M investment.

The biotech firm's revenue plummeted as losses soared. But behind the numbers is a calculated pivot to cancer therapy, fueled by a Nasdaq debut and new cash.

A new AI agent from a JetBrains spin-off aims to automate social media strategy, freeing creators to focus on their craft and build profitable businesses.